Aytu BioScience Earnings Call: ExuA Launch vs. Headwinds

Aytu BioScience ((AYTU)) has held its Q2 earnings call. Read on for the main highlights of the call.

Aytu BioScience’s latest earnings call painted a cautiously optimistic picture, balancing the excitement of the ExuA launch with short-term financial pressure. Management highlighted strong early commercial traction, resilient ADHD revenue and tighter launch spending, even as lower net revenue, margin compression and a large non-cash warrant loss weighed on reported results.

ExuA Launch Positions Aytu in First-in-Class MDD Segment

Aytu officially launched ExuA, the first and only FDA-approved 5-HT1A agonist for major depressive disorder, marking a strategic move into differentiated CNS therapy. The company is rolling out a multi-channel promotional plan, aiming to build awareness among psychiatrists and primary care physicians while leveraging its existing commercial infrastructure.

Early Prescriber Uptake and Patient Response Show Momentum

Within roughly 30 days of launch, over 100 physicians in 27 states had written ExuA prescriptions, with first refills already emerging. Management reported that initial patient feedback has been positive, with the drug generally well tolerated, though they cautioned that these early metrics cover a short time frame and were partly impacted by weather-related disruptions.

RxConnect Underpins Access, Pricing and Payer Reach

The Aytu RxConnect platform is central to ExuA market access, capping out-of-pocket costs at $50 for commercially insured patients and streamlining fulfillment. This hub-and-dispense model is also guiding payer contracting, which now covers about 60% of commercially insured MDD patients, and it already dispenses roughly 85% of Aytu’s branded ADHD prescriptions.

ADHD Franchise Demonstrates Resilience Amid Portfolio Shift

Aytu’s ADHD portfolio delivered $13.2 million in net revenue, only about 4.3% lower than the $13.8 million reported a year ago and essentially flat versus the prior quarter. This stability came despite Salesforce reprioritization toward ExuA and the recent entry of generic competition, underscoring the durability of the ADHD business as a cash engine.

Pediatric Segment Shows Sequential Rebound and Stabilization

The pediatric portfolio posted a strong sequential recovery, with net revenue rising from $0.715 million in Q1 to $1.7 million in Q2, a jump of roughly 138%. Management framed this as evidence that the pediatric business is stabilizing after prior-quarter pressure from returns, adding a modest but improving revenue stream alongside ADHD.

Launch Spend Cut Without Sacrificing Commercial Execution

The company trimmed its ExuA launch budget from an initial $10 million plan to under $8 million, citing execution efficiencies and resource discipline. Around $3 million of this reduced budget is one-time in nature, allowing Aytu to support a national launch while maintaining some control over cash burn and operating leverage.

Supply Chain Ready for Higher-Than-Expected ExuA Demand

Management emphasized that ExuA supply is not a constraint, with adequate finished product and active pharmaceutical ingredient on hand at the contract manufacturer. They indicated that production can scale substantially beyond initial runs if demand outpaces internal forecasts, reducing the risk of stock-outs during the critical launch phase.

Net Revenue Declines Modestly Despite Portfolio Reprioritization

Total net revenue for the quarter came in at $15.2 million versus $16.2 million in the prior-year period, a decline of about 6.2%. The year-over-year drop reflects lower contributions from deemphasized legacy products more than any deterioration in the core ADHD franchise, which remained relatively steady.

Gross Margin Hit by Adzenys Write-Down but Underlying Strength Intact

Reported gross margin compressed to 63.5% from 66.5% a year ago, pressured by a $600,000 inventory write-down tied to branded Adzenys. Excluding this charge, gross margin would have been 67.4%, suggesting the core profitability profile of the portfolio remains solid despite mix shifts and launch-related noise.

Non-Cash Warrant Loss Drives Swing to Large Net Loss

Aytu reported a net loss of $10.6 million, or $1.05 per share, compared with net income of $0.8 million, or $0.13 per share, in the year-ago quarter. The swing was driven largely by an $8.2 million non-cash derivative warrant liability loss versus a $3.0 million gain last year, making headline earnings highly sensitive to stock-price-related accounting rather than operations.

Adjusted EBITDA Turns Negative on Launch Investments

Adjusted EBITDA moved to a loss of $0.8 million from a positive $1.3 million a year earlier as ExuA launch spending ramped and revenue from legacy products declined. This shift underscores that Aytu is currently investing through the P&L to support long-term growth, with the near-term trade-off being reduced profitability metrics.

Operating Expenses Rise with Launch and Regulatory Costs

Operating expenses excluding amortization and restructuring rose to $11.1 million from $10.2 million, an increase of roughly 8.8%. The higher spend primarily reflects commercial and medical support for ExuA and includes a one-time $400,000 FDA PDUFA fee, adding to near-term cost pressure but not recurring at the same level.

Generic Pressure Emerges on Adzenys but Share Holds Up

Teva’s mid-December launch of an ANDA generic to Adzenys has begun to show in prescription trends over the first six weeks of competition. Teva’s generic currently accounts for about 5% of prescriptions, Aytu’s own authorized generic about 20%, and the remainder remains branded, though management cautioned that continued generic encroachment could pressure ADHD revenue over time.

Cash Position Solid but Capital Structure Adds Volatility

Cash and cash equivalents declined sequentially from $32.6 million to $30.0 million, an 8% drop, reflecting launch-related investments and operating losses. The company’s capital structure, with 10.7 million common shares and 8.8 million prefunded warrants outstanding, creates an effective share base of about 19.5 million and contributes to volatile non-cash derivative liability marks.

Guidance Highlights Gradual ExuA Ramp and Path to Breakeven

Management guided to a modest initial ExuA net revenue ramp in the March quarter, noting that scripts will grow faster than revenue because RxConnect covers the first two months at no cost for commercially insured patients until month-three refills in June. They advised modeling gross margins in the mid- to high-60% range, March-quarter OpEx of about $4–5 million excluding D&A, a year-end normalized OpEx run-rate near $11.6 million and breakeven at roughly $17.3 million in quarterly net revenue, with cash breakeven around $16.6 million and $30 million of cash on hand at year-end.

Aytu BioScience’s call underscored a transition phase: ExuA is off to a promising start, the ADHD franchise remains resilient and pediatric revenues are rebounding, but profitability is under pressure from launch costs, generic risk and accounting volatility. Investors will be watching prescription trends, margin trajectory and progress toward the targeted breakeven revenue run-rate as the ExuA story unfolds.